Literature DB >> 26341563

Secular trends (1990-2013) in serotypes and associated non-susceptibility of S. pneumoniae isolates causing invasive disease in the pre-/post-era of pneumococcal conjugate vaccines in Spanish regions without universal paediatric pneumococcal vaccination.

Asunción Fenoll1, Juan-José Granizo2, María-José Giménez3, José Yuste4, Lorenzo Aguilar5.   

Abstract

This study analyzed temporal trends of non-susceptibility/serotypes in invasive pneumococci from Spanish regions where pneumococcal conjugate vaccines (PCVs) were not included in paediatric immunization programmes. All invasive pneumococcal isolates voluntarily sent to the Spanish Reference Laboratory for Pneumococci (January 1990-December 2013) from hospitals located in target study regions were analyzed by age group. The PCV estimated coverage in children <24 months was correlated with 13-valent PCV (PCV13) serotypes trends. A total of 28,124 invasive isolates were analyzed: 3138 (11.2%) from children <24 months, 2161 (7.7%) from children 24-59 months, 781 (2.8%) from children 5-14 years, and 22,044 (78.4%) from adults. The estimated coverage increased from 17.6% (2002) to around 40% (2010-2013). The percentage of PCV13 serotypes among all isolates over time followed a cubic significant trend (R(2)=0.884), with an increasing trend up to 2001 followed by a decrease (more prominent from 2010 onwards). The estimated PCVs coverage was significantly correlated with the decrease in the percentage of PCV13 isolates in children <24 months (r(2)=0.824) and in adults (r(2)=0.786), mainly due to decreases in serotypes 1 and 7F in adults, and in serogroup 6 and serotypes 7F and 19A in children <24 months. None of the non-PCV13 serotypes stood out with substantial increases in the last period. This study showed that the different serotypes (and its associated non-susceptibility trends) were not equally affected by low PCVs disposition. Lack of impact in certain serotypes as serotype 1 (in children 24-59 months), 6C (in all age groups), and 19A (in adults) suggests the need for increasing vaccine coverage in the target vaccine population to increase direct and indirect protection.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Erythromycin; Levofloxacin; PCV13; Penicillin; Vaccine coverage

Mesh:

Substances:

Year:  2015        PMID: 26341563     DOI: 10.1016/j.vaccine.2015.08.009

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Factors associated with pneumococcal polysaccharide vaccination of the elderly in Spain: A cross-sectional study.

Authors:  Angela Domínguez; Núria Soldevila; Diana Toledo; Pere Godoy; Núria Torner; Luis Force; Jesús Castilla; José María Mayoral; Sonia Tamames; Vicente Martín; Mikel Egurrola; Francisco Sanz; Jenaro Astray
Journal:  Hum Vaccin Immunother       Date:  2016-04-11       Impact factor: 3.452

Review 2.  A reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in Southern Europe (2009-2016).

Authors:  Marta Moreira; Olga Castro; Melissa Palmieri; Sofia Efklidou; Stefano Castagna; Bernard Hoet
Journal:  Hum Vaccin Immunother       Date:  2016-12-20       Impact factor: 3.452

3.  Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015.

Authors:  Juan Picazo; Jesús Ruiz-Contreras; Juan Casado-Flores; Sagrario Negreira; Fernando Baquero; Teresa Hernández-Sampelayo; Enrique Otheo; Cristina Méndez
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

4.  Whole genome sequencing of macrolide resistant Streptococcus pneumoniae serotype 19A sequence type 416.

Authors:  Petra Spanelova; Vladislav Jakubu; Lucia Malisova; Martin Musilek; Jana Kozakova; Costas C Papagiannitsis; Ibrahim Bitar; Jaroslav Hrabak; Annalisa Pantosti; Maria Del Grosso; Helena Zemlickova
Journal:  BMC Microbiol       Date:  2020-07-25       Impact factor: 3.605

Review 5.  Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults.

Authors:  María-José Giménez; Lorenzo Aguilar; Juan José Granizo
Journal:  Multidiscip Respir Med       Date:  2018-11-02

Review 6.  Combination of Antibodies and Antibiotics as a Promising Strategy Against Multidrug-Resistant Pathogens of the Respiratory Tract.

Authors:  Mirian Domenech; Julio Sempere; Sara de Miguel; Jose Yuste
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

7.  Molecular characterization of serogroup 19 Streptococcus pneumoniae in the Czech Republic in the post-vaccine era.

Authors:  Helena Žemličková; Lucia Mališová; Petra Španělová; Vladislav Jakubů; Jana Kozáková; Martin Musílek; Matej Medvecký
Journal:  J Med Microbiol       Date:  2018-07       Impact factor: 2.472

8.  Seconeolitsine, the Novel Inhibitor of DNA Topoisomerase I, Protects against Invasive Pneumococcal Disease Caused by Fluoroquinolone-Resistant Strains.

Authors:  Jose Manuel Tirado-Vélez; David Carreño; David Sevillano; Luis Alou; José Yuste; Adela G de la Campa
Journal:  Antibiotics (Basel)       Date:  2021-05-13

9.  PSGL-1 on Leukocytes is a Critical Component of the Host Immune Response against Invasive Pneumococcal Disease.

Authors:  Elisa Ramos-Sevillano; Ana Urzainqui; Belén de Andrés; Rafael González-Tajuelo; Mirian Domenech; Fernando González-Camacho; Francisco Sánchez-Madrid; Jeremy S Brown; Ernesto García; Jose Yuste
Journal:  PLoS Pathog       Date:  2016-03-14       Impact factor: 6.823

10.  Integrated proteomic and metabolomic analysis reveals that rhodomyrtone reduces the capsule in Streptococcus pneumoniae.

Authors:  Watcharapong Mitsuwan; Alfonso Olaya-Abril; Mónica Calderón-Santiago; Irene Jiménez-Munguía; José Antonio González-Reyes; Feliciano Priego-Capote; Supayang P Voravuthikunchai; Manuel J Rodríguez-Ortega
Journal:  Sci Rep       Date:  2017-06-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.